- Price
- $332.70
- Day
- -0.60%
- Mkt Cap
- $8.99B
- 52W Range
- $236.73 – $343.12
- Volume
- 263.8K
- Beta
- 1.05
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Amundi grew its position in Bio-Rad Laboratories, Inc. (NYSE: BIO) by 1,763.4% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 38,778 shares of the medical research company's stock after buying an additional 36,697 shares during the
Read full article
Bio-Rad Laboratories NYSE: BIO reported second-quarter revenue of approximately $651 million, essentially flat from $652 million a year earlier on a reported basis and down 1.9% on a currency-neutral basis, as continued softness in academic research markets weighed on its Life Science segment.
Read full article
Bio-Rad Laboratories, Inc. (BIO) Q2 2026 Earnings Call Transcript
Read full article
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2026. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: “Second-quarter reported revenue was flat year-over-year, with growth in Clinical Diagnostics offset by continued softness in Life Science. Despite Life Science headwinds, our digital PCR.
Read full article
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.34 per share. This compares to earnings of $2.61 per share a year ago.
Read full article
Central Bank of Jordan Selects BIO-key for National Biometric Authentication, Aiming to Advance Biometric Authentication Across Jordan's Financial Sector
Read full article
On July 28, 2026, Bio-Rad Laboratories Inc (BIO) shares rose 4.6% to $331.00, continuing a strong upward trend with a 52-week range of $236.73 to $343.12. This
Read full article
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy
Read full article
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the second quarter of 2026 on Tuesday, August 4, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.
Read full article
Taipei, Taiwan, July 23, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the successful conclusion of YD Bio's and its affiliate EG BioMed Co., Ltd.'s (“EG BioMed”) participation at BIO Asia-Taiwan 2026, an international industry conference held in Taiwan, at the Washington State Pavilion on July 19, 2026.
Read full article
On July 23, 2026, Bio-Rad Laboratories Inc (BIO) shares rose 3.4%, bringing the current price to $316.38. The stock has exhibited a 52-week range between $236.7
Read full article
Assetmark Inc. boosted its stake in Bio-Rad Laboratories, Inc. (NYSE: BIO) by 19.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,989 shares of the medical research company's stock after purchasing an additional 6,224 shares during the quarter.
Read full article